SEC Form 4 · accession 0001209191-18-013198

KYNTRA BIO, INC. · KYNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Thomas B Neff

Officer — Chief Executive Officer · Director

Period of report

Feb 22, 2018

Accepted (ET)

Feb 23, 2018 · 9:58 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000921299

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 22, 2018	M	10,265	$2.35	A	2,955,614	D
Common Stock^F1,F2	Feb 22, 2018	S	8,749	$56.50	D	2,946,865	D
Common Stock^F1,F3	Feb 22, 2018	S	10,051	$57.43	D	2,936,814	D
Common Stock^F1	Feb 22, 2018	S	100	$58.025	D	2,936,714	D
Common Stock^F1,F4	Feb 22, 2018	S	618	$56.50	D	123,552	I	By Family Partnership
Common Stock^F1,F5	Feb 22, 2018	S	300	$57.72	D	123,252	I	By Family Partnership
Common Stock	Feb 23, 2018	M	10,265	$2.35	A	2,946,979	D
Common Stock^F1,F6	Feb 23, 2018	S	11,400	$55.90	D	2,935,579	D
Common Stock^F1,F7	Feb 23, 2018	S	6,500	$56.89	D	2,929,079	D
Common Stock^F1,F8	Feb 23, 2018	S	1,000	$57.40	D	2,928,079	D
Common Stock^F1,F9	Feb 23, 2018	S	500	$55.79	D	122,752	I	By Family Partnership
Common Stock^F1,F10	Feb 23, 2018	S	418	$57.11	D	122,334	I	By Family Partnership
Common Stock	holding	—	—		—	19,500	I	By spouse
Common Stock^F11	holding	—	—		—	60,946	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F12	$2.35	Feb 22, 2018	M	10,265	D	—	Mar 12, 2018	Common Stock	10,265	27,535	D
Stock Option (Right to Buy)^F12	$2.35	Feb 23, 2018	M	10,265	D	—	Mar 12, 2018	Common Stock	10,265	17,270	D

Explanation of responses

F1Shares sold pursuant to a 10b5-1 plan.
F10The shares were sold at prices ranging from $56.725 to $57.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F11The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F12Fully vested.
F2The shares were sold at prices ranging from $56.00 to $56.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The shares were sold at prices ranging from $57.00 to $57.925. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4The shares were sold at prices ranging from $56.125 to $57.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5The shares were sold at prices ranging from $57.60 to $57.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6The shares were sold at prices ranging from $55.35 to $56.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7The shares were sold at prices ranging from $56.35 to $57.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F8The shares were sold at prices ranging from $57.35 to $57.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F9The shares were sold at prices ranging from $55.45 to $56.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.